Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by retiredcopon Aug 10, 2018 10:36am
108 Views
Post# 28440304

RE:New Article; Biogen's Decade-Old Approach

RE:New Article; Biogen's Decade-Old Approach
SDPInvestments wrote: https://www.marketwatch.com/story/theres-new-evidence-that-the-dominant-approach-to-alzheimers-may-be-completely-wrong-2018-08-09?mod=newsviewer_click


They have a good argument that eventually it could end up being tau or something else  ... but PMN is banking on the fact that there is nothing else out there right now and if Biogen can show that they have somehting that is at least 20% effective .. its going to be approved... the need to have something is too great .... what PMN is getting ready to show is that they will have a more effective version of what will be approved ...the higher dosing capabilities will be the star of the show for PMN... I think we may have a real good idea once PMN310 is compared to all the drugs that are under clincical trials ... PMN does not want to be and most lilky will never be a company that is producing and distributing a drug ... we just want to be bought out or at the least go into a partnership  with one of the giants ...     
Bullboard Posts